Q-omics provides the consensus-scored KLRA1P profile across patient tissues and cancer cell-line models. KLRA1P expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KLRA1P is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, KLRA1P RNA expression shows 18,527 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where KLRA1P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLRA1P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLRA1P survival associations across molecular data types. KLRA1P RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLRA1P RNA expression–survival associations across cancer types. High KLRA1P expression shows unfavorable associations in KIRC and UVM, but favorable associations in BLCA, HNSC, SKCM and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KLRA1P RNA expression.
This table summarizes KLRA1P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KLRA1P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLRA1P shows lower tumor expression in UCEC and BRCA and higher tumor expression in KIRC, CHOL, LIHC and READ. The KIRC box plot shows higher KLRA1P RNA expression in tumor versus normal tissue (log2 FC = +0.610, t-test p < 0.001).
This table shows molecular features associated with KLRA1P in patient tissues and cancer cell lines. In patient samples, KLRA1P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, KLRA1P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and NCI60_ALL.
